Clinical trials: Olanzapine
Schizophrenia
Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)
This 3-part dose titration study will assess elpipodect safety, tolerability, pharmacokinetics (PK), and central nervous system activity.
- Trial name
- NCT02181803
- Testing
- Elpipodect, Base Monotherapy
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Weight Gain
Efficacy of Olanzapine on Weight Gain in Advanced Gynecologic Cancer with Paclitaxel and Carboplatin: a Double Blind, Placebo-controlled Randomized Trial
Efficacy of olanzapine on weight gain in advanced stage gynecologic cancer Proprotion of pateints in advanced stage gynecologic cancer who recieving paclitaxel and carboplatin chemotherapy gain weight on olanzapine or placebo
- Trial name
- NCT06288854
- Testing
- weight gain each group
- Where
- Thailand
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Schizophrenia
A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)
This 4-panel study will evaluate the safety, tolerability, pharmacokinetics (PK) and corrected QT interval (QTc) effect of MK-8189 versus placebo, as monotherapy in healthy participants (Panel A) including those of Japanese…
- Trial name
- MDCS (NCT03565068)
- Testing
- MK-8189, Background AAP Therapy
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism
This is a Phase 4, randomized, open-label, parallel group study designed to assess the clinical and biological effects of 12 months of treatment with long acting intramuscular (IM) aripiprazole (Abilify®) as measured by clinical…
- Trial name
- NCT02237417
- Testing
- Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Utah
Insulin Resistance, Menstrual Cycle
Effects of Antipsychotics on Brain Insulin Action in Females
Females treated with antipsychotics have higher rates of comorbid metabolic syndrome than males. Despite this, females have historically been excluded from many mechanistic studies due to confounding effects of menstrual cycles.
- Conditions
- Insulin Resistance, Menstrual Cycle, Type 2 Diabetes, Antipsychotics
- Trial name
- NCT06251635
- Testing
- Olanzapine 2.5Mg Oral Tablet, Insulin Lispro 100 UNT/ML, Saline
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
Glucose Regulation During Risperidone and Olanzapine Treatment
The overall purpose of this research is to look at how two of the most commonly prescribed newer antipsychotic medications, risperidone and olanzapine, affect substances in the body such as glucose and insulin.
- Trial name
- NCT00006195
- Testing
- risperidone, olanzapine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Antipsychotic-induced Weight Gain
The Effect of CORT118335 on Olanzapine-Induced Weight Gain
This study will investigate if there is any difference in the amount of weight gained by participants taking olanzapine with CORT118335 compared with olanzapine with placebo (a dummy test medicine which looks like CORT118335 but…
- Trial name
- NCT03877562
- Testing
- Olanzapine, CORT118335
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Healthy Adult Participants
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
This is a Phase 1, open-label, 5-period, 2-sequence, single ascending dose study designed to assess the pharmacokinetics, dose proportionality, safety, and tolerability of NRL-1004 (olanzapine nasal spray), and to assess the…
- Trial name
- NCT07921966
- Testing
- NRL-1004 2.5 mg, ZYPREXA IM 10mg, NRL-1004 5.0 mg
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Neurelis, Inc.
Weight Gain
Effects of Modafinil on Olanzapine Weight Gain
This study is designed as a 3 week, randomized, double blind, placebo controlled, trial. Olanzapine and modafinil will be titrated to 10mg and 200mg respectively.
- Trial name
- NCT00636896
- Testing
- Olanzapine plus modafinil
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Neuropsychiatric Research Institute, Fargo, North Dakota
Substance Withdrawal Syndrome
Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
Withdrawal from opioids is a clinical scenario that emergency department physicians encounter frequently. Patients who present with opioid withdrawal display symptoms such as agitation, anxiety, myalgias, abdominal pain…
- Trial name
- NCT02643355
- Testing
- Olanzapine, Clonidine
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hennepin Healthcare Research Institute
Focus of Study is on Healthy Lactating Women
Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan
This clinical lactation study is to provide information regarding the PK and amount of OLZ/SAM in breast milk and estimated infant exposure.
- Trial name
- NCT05547100
- Testing
- LYBALVI
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Schizophrenia, Diabetes
Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism
Patients suffering from schizophrenia have a high risk to become obese and develop diabetes. Risk of obesity is particularly high with some newer schizophrenia drugs, such as clozapine or olanzapine.
- Conditions
- Schizophrenia, Diabetes, Insulin Resistance
- Trial name
- NCT01160991
- Testing
- Glucose clamp technique, Amisulpride, Olanzapine
- Where
- Germany
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Pharmacokinetics
Fasted Bioequivalence Study of 2 Olanzapine Film-coated Tablets, 5 mg, in Healthy, Adult Male and Female Subjects.
This study was designed to assess the bioequivalence of Olanzapine tablets of two different manufacturers and to investigate the safety and tolerability of Olanzapine tablets of two different manufacturers.
- Trial name
- NCT05123976
- Testing
- Olanzapine film-coated tablets 5 mg (JSC Farmak, Ukraine), Zyprexa® coated tablets 5 mg (Eli Lilly, Nederland B V)
- Where
- Czechia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Joint Stock Company "Farmak"